TransMedics Group, Inc.

For the period ended Sep 30, 2025. Filed Oct 29, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Oct 29, 2025

TMDX$90.95-3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

Accumulated
Other
Comprehen- · Total
Common Stock · sive Income · Accumulated · Stockholders'
	Shares	Amount	(Loss)	Deficit	Equity
Balances at December 31, 2024	33,617,972	$697,208	$(364)	$(468,241)	$228,603
Issuance of common stock upon the exercise of common stock options	77,101	1,742	—	—	1,742
Issuance of common stock in connection with employee stock purchase plan	24,268	1,286	—	—	1,286
Restricted common stock forfeitures	(2,880)	—	—	—	—
Vesting of restricted stock units	111,419	—	—	—	—
Stock-based compensation expense	—	8,958	—	—	8,958
Foreign currency translation adjustment	—	—	37	—	37
Net income	—	—	—	25,682	25,682
Balances at March 31, 2025	33,827,880	709,194	(327)	(442,559)	266,308
Issuance of common stock upon the exercise of common stock options	192,937	7,089	—	—	7,089
Vesting of restricted stock units	18,893	—	—	—	—
Stock-based compensation expense	—	9,372	—	—	9,372
Foreign currency translation adjustment	—	—	425	—	425
Net income	—	—	—	34,907	34,907
Balances at June 30, 2025	34,039,710	725,655	98	(407,652)	318,101
Issuance of common stock upon the exercise of common stock options	55,382	1,816	—	—	1,816
Issuance of common stock in connection with employee stock purchase plan	34,728	1,963	—	—	1,963
Vesting of restricted stock units	15,157	(138)	—	—	(138)
Stock-based compensation expense	—	9,136	—	—	9,136
Foreign currency translation adjustment	—	—	3	—	3
Net income	—	—	—	24,319	24,319
Balances at September 30, 2025	34,144,977	$738,432	$101	$(383,333)	$355,200

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

Accumulated
Other · Total
Common Stock · Comprehen- · Accumulated · Stockholders'
	Shares	Amount	sive Loss	Deficit	Equity
Balances at December 31, 2023	32,670,803	$641,106	$(199)	$(503,705)	$137,202
Issuance of common stock upon the exercise of common stock options	113,023	2,547	—	—	2,547
Issuance of common stock in connection with employee stock purchase plan	9,506	638	—	—	638
Vesting of restricted stock units	58,044	—	—	—	—
Stock-based compensation expense	—	6,870	—	—	6,870
Foreign currency translation adjustment	—	—	17	—	17
Net income	—	—	—	12,197	12,197
Balances at March 31, 2024	32,851,376	651,161	(182)	(491,508)	159,471
Issuance of common stock upon the exercise of common stock options	433,398	10,641	—	—	10,641
Vesting of restricted stock units	17,772	—	—	—	—
Issuance of common stock in connection with exercise of warrants	11,735	—	—	—	—
Stock-based compensation expense	—	7,643	—	—	7,643
Foreign currency translation adjustment	—	—	(55)	—	(55)
Net income	—	—	—	12,194	12,194
Balances at June 30, 2024	33,314,281	669,445	(237)	(479,314)	189,894
Issuance of common stock upon the exercise of common stock options	206,275	6,439	—	—	6,439
Issuance of common stock in connection with employee stock purchase plan	21,797	1,423	—	—	1,423
Issuance of restricted common stock	4,160	—	—	—	—
Net issuance of common stock upon vesting of restricted stock units	15,004	—	—	—	—
Stock-based compensation expense	—	7,944	—	—	7,944
Foreign currency translation adjustment	—	—	4	—	4
Net income	—	—	—	4,216	4,216
Balances at September 30, 2024	33,561,517	$685,251	$(233)	$(475,098)	$209,920

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.